Beneficial effects of cathepsin inhibition to prevent chemotherapy-induced intestinal mucositis

Clinical and Experimental Immunology

Volumn 162, Issue 2, 2010, Pages 298-305

  Alamir, I ^a   Boukhettala, N ^a   Aziz, M ^b   Breuille D ^c   Dechelotte P ^a,b   Coeffier M ^a,b  

^a UNIVERSITÉ DE ROUEN   (France)

^b ROUEN UNIVERSITY HOSPITAL   (France)

^c NESTLÉ RESEARCH CENTER   (Switzerland)

Author keywords

Chemotherapy; E64; Intestine; Lysosome; Mucositis

Indexed keywords

CATHEPSIN B; CATHEPSIN D; CATHEPSIN H; CATHEPSIN L; CYTOKINE INDUCED NEUTROPHIL CHEMOATTRACTANT; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; METHOTREXATE; N [N (3 CARBOXYOXIRANE 2 CARBONYL)LEUCYL]AGMATINE; PEPSTATIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CELL INFILTRATION; CONTROLLED STUDY; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG EFFECT; DRUG INHIBITION; ENTERITIS; ENZYME ACTIVITY; EXOCYTOSIS; FOOD INTAKE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY CELL; INTESTINE EXOCYTOSIS; INTESTINE INJURY; INTESTINE MUCOSITIS; INTESTINE NECROSIS; INTESTINE VILLUS; INTESTINE VILLUS ATROPHY; JEJUNUM; LYSOSOME; MALE; MUCOSA INFLAMMATION; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BODY WEIGHT; CATHEPSIN D; CATHEPSINS; CHEMOKINES, CXC; EATING; GENE EXPRESSION; INFLAMMATION; INTERLEUKIN-1BETA; INTESTINAL MUCOSA; LEUCINE; MALE; METHOTREXATE; MUCOSITIS; PEPSTATINS; PEPTIDE HYDROLASES; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, SPRAGUE-DAWLEY; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78649283330     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2010.04220.x     Document Type: Article

References (23)

1. Logan RM, Gibson RJ, Bowen JM, Stringer AM, Sonis ST, Keefe DM. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41.
2. Keefe DM, Cummins AG, Dale BM, Kotasek D, Robb TA, Sage RE. Effect of high-dose chemotherapy on intestinal permeability in humans. Clin Sci (Lond) 1997; 92:385-9.
3. Keefe DM, Brealey J, Goland GJ, Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632-7.
4. Logan RM, Stringer AM, Bowen JM, Gibson RJ, Sonis ST, Keefe DM. Serum levels of NFkappaB and pro-inflammatory cytokines following administration of mucotoxic drugs. Cancer Biol Ther 2008; 7:1139-45.
5. Carneiro-Filho BA, Lima IP, Araujo DH et al. Intestinal barrier function and secretion in methotrexate-induced rat intestinal mucositis. Dig Dis Sci 2004; 49:65-72.
6. Stringer AM, Gibson RJ, Logan RM et al. Chemotherapy-induced diarrhea is associated with changes in the luminal environment in the DA rat. Exp Biol Med (Maywood) 2007; 232:96-106.
7. Stringer AM, Gibson RJ, Logan RM, Bowen JM, Yeoh AS, Keefe DM. Faecal microflora and beta-glucuronidase expression are altered in an irinotecan-induced diarrhoea model in rats. Cancer Biol Ther 2008; 7:1919-25.
8. Boukhettala N, Leblond J, Claeyssens S et al. Methotrexate induces intestinal mucositis and alters gut protein metabolism independently of reduced food intake. Am J Physiol Endocrinol Metab 2009; 296:E182-90.
9. Leblond J, Le Pessot F, Hubert-Buron A et al. Chemotherapyinduced mucositis is associated with changes in proteolytic pathways. Exp Biol Med (Maywood) 2008; 233:219-28.
10. Hausmann M, Obermeier F, Schreiter K et al. Cathepsin D is up-regulated in inflammatory bowel disease macrophages. Clin Exp Immunol 2004; 136:157-67.
11. Menzel K, Hausmann M, Obermeier F et al. Cathepsins B, L and D in inflammatory bowel disease macrophages and potential therapeutic effects of cathepsin inhibition in vivo. Clin Exp Immunol 2006; 146:169-80.
12. Leblond J, Hubert-Buron A, Bole-Feysot C, Ducrotte P, Dechelotte P, Coeffier M. Regulation of proteolysis by cytokines in the human intestinal epithelial cell line HCT-8: role of IFNgamma. Biochimie 2006; 88:759-65.
13. Boukhettala N, Ibrahim A, Claeyssens S et al. A diet containing whey protein, glutamine and TGFβ modulates gut protein metabolism during chemotherapy-induced mucositis in rats. Dig Dis Sci 2010; 55:2172-81.
14. Visekruna A, Joeris T, Seidel D et al. Proteasome-mediated degradation of IkappaBalpha and processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 2006; 116:3195-203.
15. Fitzpatrick LR, Small JS, Poritz LS, McKenna KJ, Koltun WA. Enhanced intestinal expression of the proteasome subunit low molecular mass polypeptide 2 in patients with inflammatory bowel disease. Dis Colon Rectum 2007; 50:337-48. discussion 348-50.
16. Inoue S, Nakase H, Matsuura M et al. The effect of proteasome inhibitor MG132 on experimental inflammatory bowel disease. Clin Exp Immunol 2009; 156:172-82.
17. Coeffier M, Gloro R, Boukhettala N et al. Increased proteasomemediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105:1181-8.
18. Bryant PW, Lennon-Dumenil AM, Fiebiger E, Lagaudriere-Gesbert C, Ploegh HL. Proteolysis and antigen presentation byMHCclass II molecules. Adv Immunol 2002; 80:71-114.
19. Briozzo P, Badet J, Capony F et al. MCF7 mammary cancer cells respond to bFGF and internalize it following its release from extracellular matrix: a permissive role of cathepsin D. Exp Cell Res 1991; 194:252-9.
20. Koike M, Nakanishi H, Saftig P et al. Cathepsin D deficiency induces lysosomal storage with ceroid lipofuscin in mouse CNS neurons. J Neurosci 2000; 20:6898-906.
21. Zaidi N, Burster T, Sommandas V et al. A novel cell penetrating aspartic protease inhibitor blocks processing and presentation of tetanus toxoid more efficiently than pepstatin A. Biochem Biophys Res Commun 2007; 364:243-9.
22. Zaidi N, Maurer A, Nieke S, Kalbacher H. Cathepsin D: a cellular roadmap. Biochem Biophys Res Commun 2008; 376:5-9.
23. Glickman MH, Ciechanover A. The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev 2002; 82:373-428.